FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Creating Hope Reauthorization Act Introduced

Sen Susan Collins and a bipartisan group of her colleagues introduce the Creating Hope Reauthorization Act to extend until 2030 the FDA priority revie...

latest-news-card-1
Human Drugs

Change Biological Drug Monographs: Petition

A University of Illinois Chicago College of Pharmacy petition calls on FDA to authorize a new form of monograph for biological products.

latest-news-card-1
FDA General

Advisors Surveyed on Committee Reforms

3D Communications shares the results from its survey of FDA advisory committee members on committee reform issues.

Medical Devices

Surgical Plannings New HipInsight Cleared

FDA clears a Surgical Planning Associates 510(k) for its new HipInsight 2.0 mixed-reality guidance system for hip arthroplasty.

latest-news-card-1
Human Drugs

Clinical Hold Removed on Dravet Syndrome Drug

FDA removes a partial clinical hold on Stoke Therapeutics zorevunersen (STK-001) and its use in children and adolescents with Dravet syndrome.

latest-news-card-1
Human Drugs

FDA Clears BioVie for Parkinsons Trial

FDA gives BioVie the go-ahead to begin its Phase 2 SUNRISE-PD trial in Parkinsons disease patients.

latest-news-card-1
Federal Register

Panel to Discuss Ocaliva Confirmatory Data

Federal Register notice: FDA announces a 9/13 advisory committee meeting to discuss an Intercept Pharmaceuticals supplemental NDA for Ocaliva (obetich...

latest-news-card-1
Federal Register

Meeting on New Rare Disease Therapies Hub

Federal Register notice: FDA announces a 10/16 public meeting entitled Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub.

latest-news-card-1
Federal Register

FDA Withdraws Plans on Kratom/Psychedelics Research

Federal Register notice: FDA withdraws an 8/2 notice that sought comments on a proposed information collection entitled Risk/Safety Considerations and...

latest-news-card-1
Human Drugs

Lykos to Appeal MDMA Drug Rejection

After receiving a complete response letter, Lykos Therapeutics says it will pursue FDAs dispute resolution process to question the need for another st...